SpringWorks is in the air for Merck KGaA
The deal isn’t done, but would be Merck’s biggest oncology buy.
Nerviano becomes a targeted PARP player
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
